Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy

Abstract Background To mitigate the risk of stent thrombosis, patients treated by percutaneous coronary intervention (PCI) are administered dual anti-platelet therapy comprising aspirin and a platelet P2Y12 receptor inhibitor. Clopidogrel is a prodrug requiring activation by the cytochrome P450 enzy...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Abdullah M. Al-Rubaish, Fahad A. Al-Muhanna, Abdullah M. Alshehri, Mohammed A. Al-Mansori, Rudaynah A. Alali, Rania M. Khalil, Khalid A. Al Faraidy, Cyril Cyrus, Mohammed M. Sulieman, Chittibabu Vatte, Daniel M. F. Claassens, Jurriën M. ten Berg, Folkert W. Asselbergs, Amein K. Al-Ali
פורמט: Artigo
שפה:Inglês
יצא לאור: BMC 2020-06-01
סדרה:BMC Cardiovascular Disorders
נושאים:
Clopidogrel
Ticagrelor
Prasugrel
Platelet aggregation inhibitor
King Fahd hospital
Purinergic P2 receptor antagonists
גישה מקוונת:http://link.springer.com/article/10.1186/s12872-020-01558-2
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים